Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141547 | 0.83 | ELANE (0.40) | DGAT1PRKCAELANEALDH1A1TSHR | |
| SCHEMBL31361800 | 0.80 | ELANE (0.39) | DGAT1PRKCAELANEALDH1A1TSHR | |
| SCHEMBL804118 | 0.80 | ALDH1A1 (0.47) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL8664776 | 0.76 | ALDH1A1 (0.40) | DGAT1PRKCAELANEALDH1A1 | |
| SCHEMBL6821171 | 0.75 | — | — | |
| Acetic Acid SCHEMBL28518327 | 0.75 | FFAR3 (0.44) | PRKCAELANEALDH1A1TSHR | |
| SCHEMBL4328011 | 0.74 | — | — | |
| SCHEMBL15139 | 0.74 | — | — | |
| SCHEMBL247159 | 0.72 | ALDH1A1 (0.35) | PRKCAELANEALDH1A1TSHR | |
| SCHEMBL247157 | 0.72 | PRKCA (0.36) | PRKCAELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119799782-A | Modification regulation gene editing method based on sgRNA | 武汉大学中南医院 | 2025-04-11 | — | — | CN | claimed |
| EP-1077981-B1 | NOVEL CEPHALOSPORIN COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME | LG CHEMICAL LTD (KR) | 2002-08-07 | — | — | EP | claimed |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250321207-A1 | Chromatography | NOVA PRIMARY MANUFACTURING LTD (GB) | 2025-10-16 | — | — | US | disclosed |
| CN-119451666-A | Lipid nanoparticles for gene editing systems | 奥泽生物疗法公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119110732-A | Gene editing for improving joint function | 奥泽生物疗法公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119053696-A | Transmembrane receptor gene editing | 奥泽生物疗法公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-3932931-B1 | A NEBULIZER COMPRISING A PHARMACEUTICAL COMPOSITION COMPRISING 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4341266-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3897688-B9 | USE OF SAP FOR THE TREATMENT OF EUROTIOMYCETES FUNGI INFECTIONS | HUMANITAS MIRASOLE SPA (IT) | 2023-10-04 | — | — | EP | disclosed |
| EP-3897688-B1 | USE OF SAP FOR THE TREATMENT OF EUROTIOMYCETES FUNGI INFECTIONS | HUMANITAS MIRASOLE SPA (IT) | 2023-06-07 | — | — | EP | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220411434-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022246109-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-11492353-B2 | Methods and compounds for treating Paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-2937350-B9 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES INC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220227776-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | Copycat Sciences Inc. (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2022098371-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | YAN MATTHEW (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411434-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | ZC3HAV1, ZC3HAV1L, EIF2AK2 | DGAT1 885/4885PRKCA 3745/4885ELANE 2889/4885 |
| US-11492353-B2 | Methods and compounds for treating Paramyxoviridae virus infections | PNP, RPIA, HPRT1 | DGAT1 3753/4885PRKCA 1530/4885ELANE 1217/4885 |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | MTAP, PNP, NSUN2 | DGAT1 4695/4885PRKCA 666/4885ELANE 4050/4885 |
| US-20220227776-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | ACE2, ACE, PNP | DGAT1 620/4885PRKCA 1074/4885ELANE 1495/4885 |
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | ZC3HAV1, ZC3HAV1L, GDI1 | DGAT1 868/4885PRKCA 3776/4885ELANE 2797/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | DGAT1 2446/4885PRKCA 3802/4885ELANE 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.